The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells (Q39769519)

14 September 2017

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells (English)

1 reference

14 September 2017

A Roidl

1

1 reference

14 September 2017

P Foo

2

1 reference

14 September 2017

W Wong

3

1 reference

14 September 2017

C Mann

4

1 reference

14 September 2017

S Bechtold

5

1 reference

14 September 2017

H J Berger

6

1 reference

14 September 2017

S Streit

7

1 reference

14 September 2017

J E Ruhe

8

1 reference

14 September 2017

S Hart

9

1 reference

14 September 2017

A Ullrich

10

1 reference

14 September 2017

H K Ho

11

1 reference

14 September 2017

language of work or name

English

0 references

publication date

30 November 2009

1 reference

14 September 2017

1 reference

14 September 2017

29

1 reference

14 September 2017

10

1 reference

14 September 2017

1543-1552

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2009.432

14 September 2017

0 references

cites work

Mutational analysis of the tyrosine kinome in colorectal cancers

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Mechanisms underlying differential responses to FGF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Analysis of gene function in somatic mammalian cells using small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

The Y606C RET mutation causes a receptor gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Cellular signaling by fibroblast growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Evolution of the Fgf and Fgfr gene families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

ONCOMINE: a cancer microarray database and integrated data-mining platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Beare-Stevenson syndrome: Two South American patients with FGFR2 analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.432

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.432

1 reference

14 September 2017

1 reference